Last reviewed · How we verify
Neurokinin-1 receptor antagonist — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Neurokinin-1 receptor antagonist (Neurokinin-1 receptor antagonist) — Merck Sharp & Dohme LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Neurokinin-1 receptor antagonist TARGET | Neurokinin-1 receptor antagonist | Merck Sharp & Dohme LLC | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Neurokinin-1 receptor antagonist CI watch — RSS
- Neurokinin-1 receptor antagonist CI watch — Atom
- Neurokinin-1 receptor antagonist CI watch — JSON
- Neurokinin-1 receptor antagonist alone — RSS
Cite this brief
Drug Landscape (2026). Neurokinin-1 receptor antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/neurokinin-1-receptor-antagonist. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab